ArticlePloS one2015
Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Prevalence and effect on survival of pre-treatment sarcopenia in patients with hematological malignancies: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Review
- The Influence of Muscle Morphology on Oncological Outcomes: A Review.Journal of frailty, sarcopenia and falls · 2025Review
- Prognostic value of baseline body composition parameters fromAnnals of hematology · 2025Article
- Article
- Role of muscle ultrasound in frailty assessment in older adults with type 2 diabetes mellitus.BMC geriatrics · 2024Article
- Diagnosing sarcopenia with semi-automated skeletal muscle computed tomography cutoff values and the association of these muscle metrics with long-term physical exercise.Research in diagnostic and interventional imaging · 2023Article
- Importance of computed tomography muscle quality and continuous versus cut-off-based sarcopenia detection in major hepatic surgery.Annals of translational medicine · 2022Article
- Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma.Hematological oncology · 2022Review
- Prevalence of low skeletal muscle quantity and quality and their associated factors in patients before allogeneic hematopoietic stem cell transplantation.Internal and emergency medicine · 2022Article
- Article
- Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.Current oncology (Toronto, Ont.) · 2021Article
- Observational
- Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma Patients.Frontiers in nutrition · 2021Article
- Sarcopenia and low muscle radiodensity associate with impaired FEVJournal of cachexia, sarcopenia and muscle · 2020Article
- Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma.Journal of cachexia, sarcopenia and muscle · 2020Article
- Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults.Einstein (Sao Paulo, Brazil) · 2020Article
- Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly.Einstein (Sao Paulo, Brazil) · 2019Article
- Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.Journal of cachexia, sarcopenia and muscle · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle radio-density (SMD) measures muscle radiation attenuation (in Hounsfield Units, HU) on computed tomography (CT) scans. Low SMD is prognostic of poor survival in melanoma, however its significance is unknown for hematologic malignancies. We performed a single institution, retrospective review of all follicular lymphoma (FL) patients who received chemoimmunotherapy from 2004-2009. Patient demographics, FL International Prognostic Index 1 (FLIPI-1), progression free (PFS) and overall survival (OS) were collected as primary endpoints. Objective response rates (ORR) were secondary. SMD was calculated using pre-treatment CT scans. In 145 patients reviewed, median values were age 59, FLIPI-1 of 2, stage III, and 8 chemoimmunotherapy cycles received. Median PFS for those with low SMD (<36.6 and <33.1 HU for patients with BMI ≤ 25 and > 25 kg/m2, respectively) compared to those with high SMD was profoundly worse, 69.6 vs. 106.7 months (hazard ratio [HR] 1.85; p = 0.01), respectively. Median OS was not reached in patients with high SMD vs. 92.7 months in low SMD patients (HR 4.02; p = 0.0002). Multivariate analysis supported lower SMD's OS detriment (HR = 3.40; p = 0.002) independent of FLIPI-1 (HR 1.46-2.76, p = 0.05) or gender. Low SMD predicted lower ORR, 83 vs. 96% (p = 0.01). SMD predicts survival independent of FLIPI-1 and potentially chemoimmunotherapy response. SMD is an inexpensive and powerful tool that can complement FLIPI-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.